# Flamel Technologies to Host Investor & Analyst Meeting

**Lyon, France – September 19, 2016** – Flamel Technologies (NASDAQ: FLML) today announced it will host a meeting for investors and analysts on Monday, September 26, 2016. The event will take place from 8:00 a.m. – 10:30 a.m. Eastern Time (approximate time) in New York City. Please note, due to limited capacity, attendance at this event is by invitation only.

Senior management and key opinion leaders in the field of sleep medicine will provide the investment community an update on a number of the Company's platform technologies and its upcoming Phase III trial for a once nightly formulation of sodium oxybate for the treatment of narcolepsy.

A live webcast of the presentation and accompanying slides can be accessed on the "Events & Presentations" section of the Company's Investor website at www.flamel.com/investors/upcoming-events/.

**About Flamel Technologies**

Flamel Technologies SA (NASDAQ: FLML) is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs. Flamel currently markets three previously Unapproved Marketed Drugs ("UMDs") in the United States, Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection), and Akovaz™ (ephedrine sulfate injection). The Company also develops products utilizing its proprietary drug delivery platforms, Micropump® (oral sustained release microparticles platform), along with its tangent technologies, LiquiTime® (a Micropump-derivative platform for liquid oral products) and Trigger Lock™ (a Micropump-derivative platform for abuse-resistant opioids). Additionally, the Company has developed a long acting injectable platform, Medusa™, a hydrogel depot technology, particularly suited to the development of subcutaneously administered formulations. Current applications of Flamel's drug delivery products include sodium oxybate (Micropump®), extended-release of liquid medicines such as ibuprofen and guaifenesin (LiquiTime®, through a license arrangement with Elan Pharma International Limited for the U.S. Over-the-Counter market) and a current study of the delivery of exenatide utilizing the Medusa™ technology. In February 2016, Flamel acquired FSC Pediatrics, a company that markets three pediatric pharmaceutical products - Cefaclor for oral suspension, indicated for infection, Karbinal™ ER, indicated for allergic rhinitis and AcipHex®

Sprinkle™ (rabeprazole sodium) indicated for the treatment of gastroesophageal disease (GERD). FSC also received 510(k) clearance from the FDA in October 2014 for Flexichamber™, a collapsible holding chamber for used in the administration of aerosolized medication using pressurized Metered Dose Inhalers (pMDIs) for the treatment of asthma. The Company is headquartered in Lyon, France and has operations in Dublin, Ireland and in St. Louis, Missouri. Additional information may be found at www.flamel.com.

*******

**Contacts:** **Michael F. Kanan**
**Chief Financial Officer**
Phone: (636) 449-1844
E-mail: kanan@flamel.com

**Lauren Stival**
**Sr. Director, Investor Relations and Corporate Communications**
Phone: (636) 449-5866
Email: stival@flamel.com